A rational approach to uninvestigated dyspepsia in primary care: Review of the literature

Postgraduate Medical Journal

Volumn 78, Issue 926, 2002, Pages 707-716

  Arents, N L A ^a   Thijs, J C ^b   Kleibeuker, J H ^c  

^a Public Health Service of Groningen   (Netherlands)

^b Bethesda Hospital   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ACCURACY; ANALYTIC METHOD; DIFFERENTIAL DIAGNOSIS; DYSPEPSIA; ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MEDICAL LITERATURE; PRIMARY MEDICAL CARE; REVIEW;

DIAGNOSIS, DIFFERENTIAL; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PRIMARY HEALTH CARE;

EID: 0036932567     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.78.926.707     Document Type: Review

References (263)

1. Crean GP, Card WI, Beatti AD, et al. Ulcer-like dyspepsia. Scand J Gastroenterol 1982;17(suppl 79):9-15.
2. Colin-Jones DG. Management of dyspepsia: Report of a working party. Lancet 1988;i:576-9.
3. Barbara L, Camilleri M, Carinaldesi R, et al. Definitian and investigation of dyspepsia. Dig Dis Sci 1989;34:1271-6.
4. Heading RC. Definitians of dyspepsia. Scand J Gastroenterol 1991;26(suppl 182):1-6.
5. Doll R, Janes AF, Bucjatzsch MM. Occupatianal factors in the aetialogy of gastric and duadenal ulcers, with an estimate of their incidence in the general papulation. Medical Research Council Reports Series 1951;276:1-9.
6. Tibblin G. Ulcusfrekvens bland 50-ariga man. Lakartidningen 1966;63:4825-9.
7. Weir RD, Backett EM. Studies of the epidemiolagy of peptic ulcer in a rural community: Prevalence and natural histary of dyspepsia and peptic ulcer. Gut 1968;9:75-83.
8. Johnsen R, Straume B, Farde OH. Peptic ulcer disease and nan-ulcer dyspepsia-a disease and a disarder. Scand J Prim Health Care 1988;6:239-43.
9. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ 1989;298:30-32.
10. Jones RH, Lydread SE, Habbs FDR, et al. Dyspepsia in England and Scotland. Gut 1990;31:401-5.
11. Bernersen B, Jahnsen R, Straume B, et al. Tawards a true prevalence of peptic ulcer: The Sarreisa gastraintestinal disarder study. Gut 1990;31:989-92.
12. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand J Gastraenterol 1991;26(suppl 182):17-24.
13. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: A population-based study. Gastroenterology 1992;102:1259-68.
14. Agreus L, Svardsudd K, Nyren O, et al. The epidemiology of abdominal symptoms: Prevalence and demographic characteristics in a Swedish adult population. Scand J Gastroenterol 1994;29:102-9.
15. Kay L, Jorgensen T. Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol 1994;29:2-6.
16. Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996;10:83-9.
17. Nyren O. Functional dyspepsia - A disorder of the stomach ? The Stomach 1990: 385-415.
18. Holtmann G, Goebell G, Talley NJ. Dyspepsia in consulters and non-consulters: Prevalence, health-care seeking behaviour and risk factors. Eur J Gastroenterol Hepatol 1994;6:917-24.
19. Heikkinen M, Pikkarainen P, Takala J, et al. General practicioners' approach to dyspepsia. Scand J Gastroenterol 1996;31:648-53.
20. Muris JWM, Starmans R, Fijten GH, et al. Abdominal pain in general practice. Fam Pract 1993;10:387-90.
21. Warndorff DK, Knottnerus JA, Huijnen LGJ, et al. How well do general practitioners manage dyspepsia ? J R Coll Gen Pract 1989;39:499-502.
22. Bodger K, Daly MJ, Heatly RV. Prescribing patterns for dyspepsia in primary care: A prospective study of selected general practitioners. Aliment Pharmacol Ther 1996;10:889-5.
23. Anonymous. American Gastroenterology Association medical position paper: Evaluation of dyspepsia. Gastroenterology 1997;114:579-81.
24. British Society of Gastroenterology. Dyspepsia Management Guidelines. Guidelines in Gastroenterology 1996;1:1-8.
25. Numans ME, de Wit NJ, Geerdes RHM, et al. NHG-standaard maagklachten, eerste herziening. Huisarts en Wetenschap 1996;39:565-77.
26. Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterology Intl 1991;4:145-60.
27. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8.
28. Silverstein BD, Pope CE. Role of diagnostic tests in esophageal evaluation. Am J Surg 1980;139:744-8.
29. International Agency for Research on Cancer. Cancer incidence in five continents. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans 1987;88:1-970.
30. Lam SK, Talley NJ. Report of the 1997 Asia pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1997;13:1-12.
31. Heikinnen M, Pikkarainen P, Takala J, et al. Etiology of dyspepsia: Four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 1995;30:519-23.
32. Kagevi I, Lofstedt S, Persson LG. Endoscopic findings and diagnoses in unselected dyspeptic paptients at a primary health care center. Scand J Gastroenterol 1989;24:145-50.
33. Hansen JM. Dyspepsia in Primary Care. Clinical Decision Making and Pharmacotherapy in Non-organic Dyspepsia. (Thesis, Odense University, Odense, Danmark, 1995.)
34. Ayoola EA, al Rashed RS, al Mofleh IA, et al. Diagnostic yield of upper gastrointestinal endoscopy in relation to age and gender: A study of 10112 Saudi patients. Hepato-Gastroenterology 1996;43:409-15.
35. Hungin P. Open Access Gastroscopy. (Thesis, University of Newcastle upon Tyne, Newcastle upon Tyne, UK, 1995.)
36. Hallissey MT, Allum WH, Jewkes AJ, et al. Early detection of gastric cancer. BMJ 1990;301:513-15.
37. Fedail SS, Araba BM, Homeida MM, et al. Upper gastrointestinal fibreoptic endoscopy experience in the Sudan. Analysis of 2500 endoscopies. Lancet 1983;ii:897-9.
38. Mansi C, Mela GS, Pasini D, et al. Patterns of dyspepsia in patients with no clinical evidence of organic diseases. Dig Dis Sci 1990;35:1452-8.
39. Holdstock G, Wiseman M, Loehry CA. Open-access endoscopy service for general practitioners. BMJ 1979;i:457-9.
40. Fjosne U, Kleveland PM, Waldum H, et al. The clinical benefit of routine upper gastrointestinal endoscopy. Scand J Gastroenterol 1986;21:433-40.
41. Capurso L, Koch M, Dezi A, et al. Towards a quantitative diagnosis of dyspepsia: The value of clinical symptoms. Ital J Gastroenterol 1988;20:191-202.
42. Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996;110:1036-42.
43. Davenport PM, Morgan AG, Darnborough A, et al. Can preliminary screening of dyspeptic patients allow more effective use of investigational techniques? BMJ 1985;290:217-20.
44. Nyren O, Adami HO, Gustavsson S, et al. The epigastric distress syndrome - A possible disease entity identified by history and endoscopy in patients with nonulcer dyspepsia. J Clin Gastroenteral 1987;9:303-9.
45. Gear MW, Ormiston MC, Barnes RJ, et al. Endoscopic studies of dyspepsia in the community: An "open-access" service. BMJ 1980;280:1135.
46. Johannessen T, Petersen H, Kleveland PM, et al. The predicitve value of history in dyspepsia. Scand J Gastroenterol 1990;25:689-97.
47. Bytzer P, Schaffalitzky de Muckadell OB. Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy. A prospective validation study of a scoring system. Scand J Gastroenterol 1992;27:987-92.
48. Talley NJ, Weaver AL, Tesmer DL, et al. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993;105:1378-86.
49. Williams B, Luckas M, Ellingham JH, et al. Do young patients with dyspepsia need investigation? Lancet 1988;ii:1349-51.
50. Saunders JH Oliver RJ, Higson DL. Dyspepsia: Incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ 1986;292:665-8.
51. The Danish Dyspepsia Study Group. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol 2001;96:1417-21.
52. Adang RP, Ambergen AW, Talmon JL, et al. The discriminative value of patient characteristics and dyspeptic symptoms for upper gastrointestinal endoscopic findings: A study on the clinical presentation of 1,147 patients. Digestion 1996;57:118-34.
53. El-Seraq HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1997;43:327-33.
54. Baldi F, GISMAD. Prevalence of reflux esophagitis (RE) in Italy. Gastroenterology 1997;112:A63.
55. Prach AT, MacDonald TA, Hopwood DA, et al. Increasing incidence of Barrett's oesophagus: Education, enthusiasm, or epidemiology? Lancet 1997;350:933.
56. Blaser MJ. Helicobacter pylori and gastric diseases. BMJ 1998;316:1507-10.
57. Warren JR, Marshall BJ. Unidentified curved bacillus on the gastric epithelium in active chronic gastritis. Lancet 1983;i:1273-5.
58. Kuipers EJ, Thijs JC, Festen HPM. Helicobacter pylori and peptic ulcer disease. Aliment Pharmacol Ther 1995;9(suppl 2):59-69.
59. Coghlan JG, Gilligan D, Humphries H, et al. Campylobacter pylori and recurrence of duodenal ulcers: A 12 month follow-up study. Lancet 1987;ii:1109-11.
60. Lam SK, Ching CK, Lai KC, et al. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut 1997;41:43-8.
61. Marshall BJ Goodwin CS, Warren JR. Prospective double-blind trial of duodenal ulcer relapse after eradiction of Campylobacter pylori. Lancet 1988;ii:1437-42.
62. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicilline plus metronidazole on the eradicition of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328:308-12.
63. Mantzaris GJ, Hatzis A, Tamvakologos G, et al. Prospective randomised investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long term relapse rates. Dig Dis Sci 1993;38:1132-6.
64. Seppala K, Pikkarainen P, Karvonen AL, et al, group Fgus. The role of Helicobacter pylori eradication in gastric ulcer healing and relapses. Gastroenterology 1992;102:A162.
65. Seppala K Pikkarainen P, Sipponen P, et al. Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group. Gut 1995;36:834-7.
66. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 1994;35:19-22.
67. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
68. Unge P, Gad A, Eriksson K, et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993;5:325-31.
69. Forbes GM, Glaser ME, Cullen DJE, et al. Duodenal ulcer treated with Helicobacter pylori eradication: Seven year follow-up. Lancet 1994;343:258-60.
70. Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994;120:977-81.
71. Sipponen P, Seppala K, Aarynen M, et al. Chronic gastritis and gastroduodenal ulcer: A case control study on risk of coexisiting duodenal or gastric ulcer in patients with gastritis. Gut 1989;30:922-9.
72. Sipponen P, Varis K, Fraki O, et al. Cumulative 10 year risk of symptomatic duodenal and gastric ulcer disease in patients with or without chronic gastritis. Scand J Gastroenterol 1990;25:966-73.
73. Cullen DJE, Collins J, Christiansen KJ, et al. Long term risk of peptic ulcer disease in people with Helicobacter pylori infection - A community based study. Gastroenterology 1993;104(suppl 2):A60.
74. Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: Is empirical triple therapy justified? Am J Gastroenterol 1998;93:574-8.
75. Sprung DJ. The natural history of duodenal ulcer disease and how it relates to Helicobacter pylori. Am J Gastroenterol 1997;92:1655.
76. Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94:1834-40.
77. Peterson WL, Ciociola AA, Sykes DL, et al, The RBC H pylori study group. Ranitidine bismuth citrate plus darithromycin is effective for healing duodenal ulcers, eradicating Helicobacter pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251-61.
78. Schubert M, De Witt JM, Taylor CA. Prospective evaluation of the prevalence of H pylori in duodenal abd gastric ulcer: Is its role overestimated? Gastroenterology 1999;116:A305.
79. Higuchi K, Arakowa T, Fuijwara Y, et al. Is Helicobacter pylori-negative duodenal ulcer masked by the high prevalence of H pylori infection in the general population ? Am J Gastroenterol 1999;94:3083-4.
80. EUROGAST study group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-62.
81. Hansen S, Melby KK, Aase S, et al. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol 1999;34:353-60.
82. Jaskiewicz K, Louwrens HD, Woodroof CW, et al. The association of Campylobacter pylori with mucosal pathological changes in a population at risk for gastric cancer. S Afr Med J 1989;75:417-19.
83. Sipponen P, Kosunen TU, Valle J, et al. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992;45:319-23.
84. Hansson LE, Engstrand L, Nyren O, et al. Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma. Gastroenterology 1993;105:1098-103.
85. Kuipers EJ, Gracia-Casanova M, Pena AS, et al. Helicobacter pylori serology in patients with gastric carcinoma. Scand J Gastroenterol 1993;28:433-7.
86. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
87. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ 1991;302:1302-5.
88. Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
89. Talley NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991;83:1734-9.
90. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans 1994;61:1-241.
91. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-6.
92. Stolte M. Helicobacter pylori gastritis and gastric MALT-lymphoma. Lancet 1992;339:745-6.
93. Du MQ, Isaacson PG. Recent advances in our understanding of the biology and pathogenesis of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Forum Genova 1998;8:162-73.
94. Lepore MJ, Smith FB, Bonanno CA. Campylobacter-like organisms in patients with Menetriers disease. Lancet 1988;i:466.
95. Bayerdorffer E, Ritter MM, Hatz R, et al. Menetriers disease and Helicobacter pylori disease. N Engl J Med 1993;329:60.
96. Bayerdorffer E, Ritter MM, Hatz R, et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori infection - Is Helicobacter pylori a pathogenic factor in Menetriers disease? Gut 1994;35:701-4.
97. Lambert JR. The role of Helicobacter pylori in nonulcer dyspepsia: A debate for. Gastroenterol Clin North Am 1993;22:141-51.
98. Talley NJ. The role of Helicobacter pylori in nonulcer dyspepsia. A debate against. Gastroenterol Clin North Am 1993;22:153-67.
99. Armstrong D. Helicobacter pylori and dyspepsia. Scand J Gastroenterof 1996;215:38-47.
100. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999;319:1040-4.
101. Talley NJ. A critique of therapeutic trials in Helicobacter pylori positive functional dyspepsia. Gastroenterology 1994;106:1174-83.
102. Veldhuyzen van Zanten SJO. A systematic overview (meta-analysis) of outcome measures in Helicobacter pylori gastritis trials and functional dyspepsia. Scand J Gastroenterol 1993;28(suppl 199):40-3.
103. Talley NJ, Vakil N, Ballard ED, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106-11.
104. Talley NJ, Janssens J, Lauritsen K, et al. H pylori eradication therapy for non-ulcer dyspepsia. A randomized double-blind placebo controlled longterm trial. Gut 1998;43(suppl 2):A79.
105. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicting Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74.
106. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engf J Med 1998;339:1875-81.
107. Bruley des Varannes S, Flejou JF, Colin R, et al. Helicobacter pylori eradication in non-ulcer dyspepsia: A randomized, double-blind, placebo-controlled study with a 12-month follow-up. Gastroenterology 2000;118:A468.
108. Froehlich F, Convers JJ, Wietlisbach V, et al. Helicobacter pylori eradication treatment does not benefit patients with non-ulcer dyspepsia. Gastroenterology 2000;118:A469.
109. Koelz HR, Arnold R, Stolte M, et al, FROSCH Study Group. Treatment of Helicobacter pylori (Hp) does not improve symptoms of functional dyspepsia (FD). Gastroenterology 1998;114:A182.
110. Malfertheiner P, Fischbach W, Layer P, et al. Elan study proves symptomatic benefit of Helicobacter pylori eradication in functional dyspepsia (FD). Gastroenterology 2000;118:A440.
111. Miwa H, Hirose M, Kikuchi S, et al. How useful is the detection kit for antibody to Helicobacter pylori in urine (urinalisa) in clinical practice. Am J Gastroenterol 1999;94:3460-3.
112. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000;321:659-64.
113. Dhali GK, Garg PK, Sharma MP. Role of anti-Helicobacter pylori treatment in H pylori-positive and cytoprotective drugs in H pylori-negative, non-ulcer dyspepsia: Results of a randomized, double-blind, controlled trial in Asian Indians. J Gastroenterol Hepatol 1999;14:523-8.
114. Greenberg PD, Cello JP. Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia. Arch Intern Med 1999;159:2283-8.
115. David J, Lee A, Forbes N, et al. Helicobacter pylori eradication for non-ulcer dyspepsia: A prospective, double-blind, randomized placebo controlled study. Gastroenterology 1996;110:A91.
116. Passos MCF, Coelho LGV, Gloria ALF, et al. H pylori eradication for functional dyspepsia: A long-term, randomised, prospective, double-blind, placebo-controlled study. Gut 1998;43(suppl 2):A81.
117. Sheu BS, Lin CY, Lin XZ, et al. Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: A prospective controlled assessment. Am J Gastroenterol 1996;91:441-7.
118. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9.
119. Vicari JJ, Falk GW, Goldblum JR, et al. Helicobacter pylori is not a pathogenic factor in GERD or its complications. Gastroenterology 1997;112:A322.
120. Werdmuller BF, Loffeld RJ. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997;42:103-5.
121. O'Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease - Clinical implications and management. Aliment Pharmacol Ther 1999;13:117-27.
122. Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the united states. Effect of age race, and socioeconomic status. Gastroenterology 1991;100:1495-501.
123. Banatvala N, Mayo K, Megraud F, et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168:219-21.
124. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
125. Fallone CA, Barkun AN, Friedman GD, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000;95:914-20.
126. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:45-51.
127. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled trial. Lancet 2001;357:1738-42.
128. McColl KEL, Dickson A, El-Nujumi A, et al. Symptomatic benefit 1-3 years after H pylori eradication in ulcer patients: Impact of gastroesophageal reflux disease. Am J Gastroenterol 1999;95:101-5.
129. Kahn K, Greenfield S. Endoscopy in the evaluation of dyspepsia. United States 1984. Health and Public Policy Committee, American College of Physicians, Philadelphia, Pennsylvania. Ann Intern Med 1985;102:266-9.
130. Talley NJ, Silverstein MD, Agreus L, et al. AGA technical review: Evaluation of dyspepsia. Gastroenterology 1998;114:582-95.
131. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-16.
132. Hungin APS, Thomas PR, Bramble MG, et al. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract 1994;44:519-21.
133. Jones R. What happens to patients with non-ulcer dyspepsia after endoscopy? Practitioner 1988;232:75-8.
134. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: Comparison of conslters and non-consulters. J R Coll Gen Pract 1989;39:495-8.
135. Nyren O, Adami HO, Gustavsson S, et al. Social and economic effects of non-ulcer dyspepsia. Scand J Gastroenterol 1985;20(suppl 109):41-5.
136. Brown C, Rees WD Dyspepsia in general practice. BMJ 1990;300:829-30.
137. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65.
138. Lauritsen K, Aalykke C, Havelund T, et al. Effect of omeprazole in functional dyspepsia: A double-blind, randomized, placebo-controlled study. Gastroenterology 1996;110:A702.
139. Blum AL, Arnold R, Koelz HR, et al, FROSCH Study Group. Treatment of functional dyspepsia (FD) with omeprazole and ranitidine. Gastroenterology 1997;112:A73.
140. Peura DA, Kovacs TO, Metz D, et al. Low-dose lansoprazole: Effective for non-ulcer dyspepsia (NUD). Gastroenterology 2000;113:A2418.
141. Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: A placebo-controlled, double-blind study. Am J Gastroenterol 1995;90:423-30.
142. Costell DO, Sigmund C Jr, Patterson D, et al. Cisapride 20 mg bid provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. Am J Gastroenterol 1998;93:547-52.
143. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
144. Galmiche JP, Fraitag B, Filoche B, et al. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990;35:649-55.
145. Inauen W, Emde C, Weber B, et al. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: A 24 hour ambulatory combined pH and manometry study. Gut 1993;34:1025-31.
146. Koelz HR. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials. Scand J Gastroenterol 1989;156:25-36.
147. McCallum RW, Ippoliti AF, Cooney C, et al. A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N Engl J Med 1977;296:354-7.
148. Toussaint J, Gossuin A, Deruyttere M, et al. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991;32:1280-5.
149. Baldi F, Bianchi PG, Dobrilla G, et al. Cisapride versus placebo in reflux esophagitis. A multicenter double- blind trial. J Clin Gastroenterol 1988;10:614-18.
150. Arvanitakis C, Nikopoulos A, Theoharidis A, et al. Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease - A comparative randomized double-blind trial. Aliment Pharmacol Ther 1993;7:635-41.
151. Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: A double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993;7:409-15.
152. Dakkak M, Jones BP, Scott MG, et al. Comparing the efficacy of cisapride and ranitidine in oesophagitis: A double-blind, parallel group study in general practice. Br J Clin Pract 1994;48:10-14.
153. Talley NJ. Drug treatment of functional dyspepsia. Scand J Gastroenterol 1991;182:47-60.
154. Finney JS, Kinnersley N, Hughes M, et al. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998;26:312-20.
155. Dobrilla G, Comberlato M, Steele A, et al. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989;11:169-77.
156. Archimandritis A, Tzivras M, Fertakis A, et al. Cisapride, metoclopramide, and ranitidine in the treatment of severe nonulcer dyspepsia. Clin Ther 1992;14:553-61.
157. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660-73.
158. Carvalhinhos A, Fidalgo P, Freire A, et al. Cisapride compared with ranitidine in the treatment of functional dyspepsia. Eur J Gastroenterol Hepatol 1995;7:411-17.
159. Miazza B, Halter F, Brignoli R. A multicentre comparative trial in functional dyspepsia: Cisapride versus cimetidine. Gastroenterology 1993;104:A18.
160. Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. Scand J Gastroenterol 1994;29:618-23.
161. Simon B, Bergemann W, Bouzo H, et al. Prokinetic drug treatment (cisapride) is as effective as H2-blocking agent (ranitidine) in the treatment of gastric ulcer. Hepato-Gastroenterology 1991;38(suppl 1):41-5.
162. Testoni PA, Bagnolo F, Buizza M, et al. Effectiveness of cisapride in gastric ulcer. Results of a double-blind randomized trial versus ranitidine and versus cisapride plus ranitidine. J Clin Gastroenterol 1993;17:5-9.
163. Slubberod A, Glise H, Hallerback B, et al. The effect of cisapride and ranitidine as monotherapies and in combination in the treatment of uncomplicated gastric ulceration. Scand J Gastroenterol 1995;30:106-10.
164. Kerrigan DD, Taylor ME, Read NW, et al. Acid, motility, and ulcers: A comparison of cisapride with placebo in the prevention of duodenal ulcer relapse. Gut 1993;34:1042-6.
165. Food and Drug Administration. FDA Warnings for Cisapride. Rockville, MD: Department of Public Health and Human Services, 2000: 24:(Jan).
166. Sobala GM, Crabtree JE, Pentith JA, et al. Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991;338:94-6.
167. Mendall MA, Goggin PM, Marrero .JM, et al. Role of Helicobacter pylori serology in screening prior to endoscopy. Eur J Gastroenterol Hepatol 1992;4:713-17.
168. Mendall MA, Jazrawi RP, Marrero JM, et al. Serology for Helicobacter pylori compared with symptom questionnaires in screening before direct access endoscopy. Gut 1995;36:330-3.
169. Tham TC, McLaughlin N, Hughes DF, et al. Possible role of Helicobacter pylori serology in reducing endoscopy workload. Postgrad Med J 1994;70:809-12.
170. Patel P, Mendall MA, Khulusi S, et al. Salivary antibodies to Helicobacter pylori: Screening dyspeptic patients before endoscopy. Lancet 1994;344:511-12.
171. Collins JSA, Bamford KB, Sloan JM, et al. Screening for Helicobacter pylori antibody could reduce endoscopy workload in young dyspeptic patients. Eur J Gastroenteroi Hepatol 1992;4:991-3.
172. Vyas SK, Sharpstone D, Treasure J, et al. Pre-endoscopy screening using serodiagnosis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1994;6:783-5.
173. Werdmuller BF, der Putten AB, Veenendaal RA, et al. Can screening for IgG antibodies against Helicobacter pylori be used in clinical practice? Omit endoscopy in seropositive or seronegative patients? Dig Dis Sci 1998;43:2296-300.
174. Vaira D, Stanghellini V, Menegatti M, et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology: A safe policy? The Italian Helicobacter pylori Study Group. Endoscopy 1997;29:595-601.
175. Reilly TG, Stone D, Poxon V, et al. H. pylori serology in the investigation of dyspepsia: A general practice based follow-up study. Gut 1996;38(suppl 1):A65.
176. Patel P, Khulusi S, Mendall MA, et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995;346:1315-18.
177. Asante AA, Mendall M, Patel P, et al. A randomized trial of endoscopy vs no endoscopy in the management of seronegative Helicobacter pylori dyspepsia. Eur J Gastroenterol Hepatol 1998;10:983-9.
178. Fendrick AM, Chernew ME, Hirth RA, et al. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995;123:260-8.
179. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: A decision analysis. Gastroenterology 1996;110:72-83.
180. Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol 1996;91:1773-7.
181. Briggs AH, Sculpher MJ, Logan RP, et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ 1996;312:1321-5.
182. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: A cost-utility study. J Fam Pract 1997;44:545-55.
183. Ofman JJ, Etchason J, Fullerton S, et al. Management strategies For Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences. Ann Intern Med 1997;126:280-91.
184. Laheij RJ, Severens JL, Jansen JB, et al. Management in general practice of patients with persistent dyspepsia. A decision analysis. J Clin Gastroenterol 1997;25:563-7.
185. Olson AD, Deutsch D. Combined empiric treatment and specific Hp screening and treatment decrease the cost of evaluating epigastric abdominal pain. Gastroenterology 1998;114:A248.
186. Heaney A, Collins JSA, Watson RGP, et al. A prospective randomised trial of a test- and-treat policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45:186-90.
187. Jones R, Tait C, Sladen G, et al. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Ciin Pract 1999;53:413-16.
188. Lassen AT, Pedersen FM, Bytzer P, et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial. Lancet 2000;356:455-60.
189. Laheij RJ, Severens JL, van de Lisdonk EH, et al. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: A cost-effectiveness analysis. Aliment Pharmacol Ther 1998;12:1249-56.
190. Duggan A, Elliot C, Tolley K, et al. Randomised controlled trial of four dyspepsia management strategies in primary care with 12 months follow-up. Gastroenterology 2000;118:A438.
191. Arents NLA, Thijs JC, Zwet van AA, The SENSE Study Working Party. Screening and treating for Helicobacter pylori ("test-and-treat" strategy) in dyspepsia reduces the number of endoscopies and leads to a similar clinical outcome as prompt endoscopy. Gastroenterology 2001;120:A89.
192. Klinkenberg-Knol EC, Jansen JM, Festen HP, et al. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987;i:349-51.
193. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
194. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(supp 1):3-7.
195. Lauritsen K, Rune SJ, Bytzer P, et al. Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med 1985;312:958-61.
196. Bardhan KD, Bianchi PG, Bose K, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 1986;8:408-13.
197. Lanza F, Goff J, Scowcroft C, et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. Am J Gastroenterol 1994;89:1191-200.
198. Farup PG, Larsen S, Ulshagen K, et al. Ranitidine for non-ulcer dyspepsia. A clinical study of the symptomatic effect of ranitidine and a classification and characterization of the responders to treatment. Scand J Gastroenterol 1991;26:1209-16.
199. Johannessen T, Kristensen P, Petersen H, et al. The symptomatic effect of 1-day treatment periods with cimetidine in dyspepsia. Combined results from randomized, controlled, single-subject trials. Scand J Gastroenterol 1991;26:974-80.
200. Johannessen T, Fjosne U, Kleveland PM, et al. Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol 1988;23:327-36.
201. Smith PM, Troughton AH, Gleeson F, et al. Pirenzepine in non-ulcer dyspepsia: A double-blind multicentre trial. J Int Med Res 1990;18:16-20.
202. Talley NJ, McNeil D, Hayden A, et al. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986;91:149-56.
203. Gad A, Dobrilla G. Campylobacter pylori and non-ulcer dyspepsia. The final results of a double-blind multicentre trial for treatment with pirenzepine in Italy. Scand J Gastroenterol 1989;167:39-43.
204. Rabeneck L, Souchek J, Wristers K, et al. Management of uninvestigated dyspepsia: A randomized, double-blind, placeo-controlled trial of proton pump inhibitor therapy. Gastroenterology 2001;119:A468.
205. Koelz HR, Birchler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986;91:1198-205.
206. Graham DY, Colon-Pagan J, Morse RS, et al. Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: A double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. Gastroenterology 1992;102:1289-94.
207. Jones R, Lydeard S. Dyspepsia in the community: A follow-up study. Br J Clin Pract 1992;46:95-7.
208. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-77.
209. Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995;109:671-80.
210. Unge P, Jonsson B, Stalhammar NO. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. Pharmacoeconomics 1995;8:410-27.
211. Hameeteman W. Columnar-lined (Barrett's) Esophagus. (Thesis, University of Amsterdam, Amsterdam, The Netherlands, 1989.)
212. Mann NS, Tsai MF, Nair PK. Barrett's esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 1989;84:1494-6.
213. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
214. van der Burgh A, Dees J, Hop WC, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
215. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984;87:927-33.
216. Van der Veen AH, Dees J, Blankensteijn JD, et al. Adenocarcinoma in Barrett's oesophagus: An overrated risk. Gut 1989;30:14-18.
217. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
218. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20.
219. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: A population-based study. Am J Gastroenterol 1999;94:86-91.
220. Smith AM, Maxwell-Armstrong CA, Welch NT, et al. Surveillance for Barrett's oesophagus in the UK. Br J Surg 1999;86:276-80.
221. van Sandick JW, Bartelsman JF, van Lanschot JJ, et al. Surveillance of Barrett's oesophagus: Physicians' practices and review of current guidelines. Eur J Gastroenterol Hepatol 2000;12:111-17.
222. Richter JE, Falk GW. Barrett's esophagus and adenocarcinoma. The need for a consensus conference. J Clin Gastroenterol 1996;23:88-90.
223. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA 2001;285:2331-8.
224. Johansson KE, Tibbling L. Maintenance treatment with ranitidine compared with fundoplication in gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:779-88.
225. Negre JB, Markkula HT, Keyrilainen O, et al. Nissen fundoplication. Results at 10 year follow-up. Am J Surg 1983;146:635-8.
226. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992;326:786-92.
227. Griffin SM, Raimes SA. Proton pump inhibitors may mask early gastric cancer. Dyspeptic patients over 45 should undergo endoscopy before these drugs are started. BMJ 1998;317:1606-7.
228. Breslin NP, Thomson ABR, Bailey RJ, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dysplasia. Gut 2000;46:93-97.
229. Christie J, Shepherd NA, Codling BW, et al. Gastric cancer below the age of 55: Implications for screening patients with uncomplicated dyspepsia. Gut 1997;41:513-17.
230. Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999;94:75-9.
231. Leodolter A, Dominguez-Munoz JE, von Arnim U, et al. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999;94:2100-4.
232. Savarino V, Mela GS, Zentilin P, et al. Comparison of isotope ratio mass spectrometry and nondispersive isotope-selective infrared spectroscopy for 13C-urea breath test. Am J Gastroenterol 1999;94:1203-8.
233. Vaira D, Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. Lancet 1999;354:30-3.
234. Vaira D, Malfertheiner P, Megraud F, et al. Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: A European multicenter study. Am J Gastroenterol 2000;95:925-9.
235. Arents NLA, van Zwet AA, Thijs JC, et al. The accuracy of the Helicobacter pylori stool antigen test in diagnosing H pylori in treated and untreated patients. Eur J Gastroenterol Hepatol 2001;13:383-6.
236. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
237. van der Wouden EJ, Thijs JC, van Zwet AA, et al. Six year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease. Gut 1998;43(suppl 2):A100.
238. Bell GD, Powell KU, Burridge SM, et al. Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: Implications for treatment of patients with duodenal ulcer disease. Q J Med 1993;86:375-82.
239. Abu-Mahfouz MZ, Prasad VM, Santogade P, et al. Helicobacter pylori recurrence after successful eradication: 5-Year follow-up in the United States. Am J Gastroenterol 1997;92:2025-8.
240. Borody TJ, Andrews P, Mancuso N, et al. Helicobacter pylori reinfection rate, in patients with cured duodenal ulcer. Am J Gastroenterol 1994;89:529-32.
241. Borody T, Andrews P, Mancuso N, et al. Helicobacter pylori reinfection 4 years post- eradication. Lancet 1992;339:1295.
242. van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: A prospective long-term follow-up study. Gastroenterology 1997;113:1082-6.
243. Uemura N, Mukai T, Okamoto S, et al. Helicobacter pylori eradication inhibits the growth of intestinal type of gastric cancer in initial stage. Gastroenterology 1996;110:A282.
244. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
245. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104:1356-70.
246. Mowat C, Williams C, Gillen D, et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 2000;119:339-47.
247. Uemura N, Okamoto S, Yamamoto S, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in japan. Aliment Pharmacol Ther 2000;14:1345-52.
248. Genta RM. Atrophy, acid suppression and Helicobacter pylori infection: A tale of two studies. Eur J Gastroenterol Hepatol 1999;11 (suppl 2):S29-S33.
249. Bell GD, Powell K, Burridge SM, et al. Experience with "triple" anti-Helicobacter pylori eradication therapy: Side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992;6:427-35.
250. Thijs JC, van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993;28:934-8.
251. Thijs JC, van Zwet AA, Moolenaar W, et al. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: A multicenter, prospective, randomized, controlled study of efficacy and side effects. Am J Gastroenterol 1996;91:93-7.
252. Marshall BJ, Hoffman SR, McCallum RW. Incidence of side effects during bismuth subsalicylate and antibiotic therapy for H pylori (HP). Gastroenterology 1992;100:A117.
253. de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: Should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995;30:401-7.
254. Houben MH, van de Beek D, Hensen EF, et al. Helicobacter pylori eradication therapy in The Netherlands. Scand J Gastroenterol 1999;34(suppl 230):17-22.
255. van der Wouden EJ, Thijs JC, van Zwet AA, et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitromidazole containing anti-Helicobacter pylori regimens: A meta-analysis. Am J Gastroenterol 1999;94:1751-9.
256. Laheij RJ, Rossum LG, Jansen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection - A meta-analysis. Aliment Pharmacol Ther 1999;13:857-64.
257. Schmid CH, Whiting G, Cory D, et al. Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: A meta-regression analysis of randomized, controlled trials. Am J Ther 1999;6:25-36.
258. Unge P, Berstad A. Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroenterol 1996;220:27-40.
259. van der Wouden EJ, van Zwet AA, Vosmaer GD, et al. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis 1997;3:385-9.
260. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pyrori. Gastroenterology 1998;115:1278-82.
261. de Boer WA. How to achieve a near 100% cure rate for H pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996;22:313-16.
262. Schutze K, Hentschel E, Dragosics B, et al. Helicobacter pylori reinfection with identical organisms: Transmission by the patients' spouses. Gut 1995;36:831-3.
263. Graham DY. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 1997;350:70-1.